Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Fineline Cube Apr 21, 2026
Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Fineline Cube Apr 21, 2026
Company Deals

ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform

Fineline Cube Apr 7, 2025

South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement...

Company

BeiGene Halts Ociperlimab Clinical Program for Lung Cancer

Fineline Cube Apr 7, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist formerly known as...

Company Deals

Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology

Fineline Cube Apr 7, 2025

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement...

Company Medical Device

MicroPort Endovascular’s Talos Stent Approved in Brazil for Aortic Dissection

Fineline Cube Apr 7, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...

Company Drug

Fujian Kerui’s Generic Sirolimus Gel Approved by China’s NMPA

Fineline Cube Apr 7, 2025

China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer’s (NYSE: PFE)...

Company Deals

Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies

Fineline Cube Apr 3, 2025

US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American...

Company Deals Medical Device

Yuewei Medtech Secures RMB100 Million in Series A++ Funding for Cardiac Device Development

Fineline Cube Apr 3, 2025

Beijing Yuewei Medical Technology Co., Ltd, a medical device company specializing in coronary heart disease,...

Company

Boehringer Ingelheim Reports 6.1% Sales Growth in 2024, Bolstered by Key Pharmaceuticals

Fineline Cube Apr 3, 2025

Germany-based Boehringer Ingelheim released its 2024 financial report, recording group net sales of EUR 26.8...

Company Deals

GE Healthcare Partners with Probo Medical to Distribute Ultrasound Devices

Fineline Cube Apr 3, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has entered...

Company Drug

Henlius Biotech’s HLX04-O Shows Positive Results in wAMD Phase III Trial

Fineline Cube Apr 3, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced positive results from the Phase III...

Company Drug

Mabwell Bioscience’s 7MW3711 ADC Receives Clinical Trial Approval in China

Fineline Cube Apr 3, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that it has received clinical trial...

Company Deals

Sinovac Partners with CPMA to Advance Vaccine Preventable Disease Initiatives

Fineline Cube Apr 3, 2025

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has entered into a strategic memorandum of understanding (MoU)...

Company Drug

Novartis’ Vanrafia Gets FDA Accelerated Approval for IgAN

Fineline Cube Apr 3, 2025

Switzerland-based Novartis (NYSE: NVS) announced that it has received accelerated approval from the US Food...

Company Deals

Sanofi and Cathay Capital Launch RMB 2 Billion Pharma Innovation Fund in China

Fineline Cube Apr 3, 2025

The Sanofi Cathy Capital Pharmaceutical Innovation Fund, a joint venture between French pharmaceutical giant Sanofi...

Company Medical Device

Sihuan Pharma’s Polycaprolactone Microsphere Filler Gains NMPA Approval

Fineline Cube Apr 3, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has received Category III...

Company Deals Drug

Shionogi Partners with Link Medical for Cefiderocol Development in Australia and New Zealand

Fineline Cube Apr 3, 2025

Japan-based Shionogi Co., Ltd. has entered into an exclusive licensing agreement with Link Medical Products...

Company Deals

WuXi XDC Partners with MABSOFT to Advance Innovative ADC Development

Fineline Cube Apr 3, 2025

China-based WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi...

Company Drug

Guojian Qingke Biomedical Gains NMPA Approval for 3D MSCs in Stroke Trials

Fineline Cube Apr 3, 2025

China-based Guojian Qingke Biomedical Technology (Beijing) Co., Ltd. announced that it has received tacit clinical...

Company Drug

Gan & Lee Pharmaceuticals Secures Pakistan Approval for Insulin Glargine Cartridge

Fineline Cube Apr 3, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) has announced the receipt of marketing approval for its...

Company Drug

Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s

Fineline Cube Apr 3, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from...

Posts pagination

1 … 171 172 173 … 654

Recent updates

  • China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive
  • FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer
  • Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases
  • Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026
  • Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Company Digital

Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases

Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.